Click to Share
 
 
  1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution
Filter News
Show All Results
News By Country
News By Tag
Spinal Muscular Atrophy Remove


April 2014
Fr Th We Tu Mo Su Sa
18 17 16 15 14 13 12

spinal muscular atrophy Press Releases

  + XML/RSS  



By Families of SMA
This is the fourth drug discovery project funded by Families of SMA in 2013 with a total investment of $550,000.

By Families of SMA
This funding will build on the consensus statement for the standard of care for SMA with data driven results on specific areas of SMA care such as respiratory, nutritional, and surgical interventions.

By Families of SMA
This three-year multi-million dollar cooperative agreement to Brian Kaspar, PhD, principal investigator in the Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital in the amount of $3,752,462, funds pre-clinical drug...

By Families of SMA
Repligen Corporation announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Repligen’s spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

By Families of SMA
The SMA community now has 3 clinical trials testing new SMA therapies, and an additional 10 programs in earlier stages of the drug development pipeline.

By FSMA
Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study of ISIS-SMNRx in patients with spinal muscular atrophy (SMA). Isis is developing ISIS-SMNRx as a potential treatment for all types of SMA.

By Families of SMA
Awards to help develop new therapies for SMA. These new awards encompass $745,000 for the basic research portion of the $3 Million in new research funding that FSMA announced earlier this year.

By FSMA
The new funding awards will be allocated into three distinct research areas: 1)Basic Research to understand the disease, 2)Drug Discovery to develop new SMA therapies, and 3)Clinical Research to provide the means to test new drugs effectively.

All Press Releases

By Families of SMA
This is the fourth drug discovery project funded by Families of SMA in 2013 with a total investment of $550,000.

By Families of SMA
This funding is being awarded to Co-Principal Investigators Dr. Arthur Burghes at Ohio State University and Dr. Christian Lorson at University of Missouri.

By Families of SMA
15 new drugs now in development for SMA. 3 in active clinical trials. 11 companies investing in SMA drug programs.

By Families of SMA
This funding will build on the consensus statement for the standard of care for SMA with data driven results on specific areas of SMA care such as respiratory, nutritional, and surgical interventions.

By Families of SMA
This three-year multi-million dollar cooperative agreement to Brian Kaspar, PhD, principal investigator in the Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital in the amount of $3,752,462, funds pre-clinical drug...

By Families of SMA
Dr. Rubin's project at Harvard is the first of three drug discovery awards that will be given by Families of SMA in the next few months.

By Families of SMA
Repligen Corporation announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Repligen’s spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

By Families of SMA
Families of SMA is dedicated to creating a treatment and cure for Spinal Muscular Atrophy by funding and advancing a comprehensive research program.

By Families of SMA
Continued investment in basic research leads to greater understanding of the exact nature, causes, and consequences of SMA.

By Families of SMA
This new research funding will support a project at Northwestern University to better understand when and where SMN protein is needed in less severe SMA.

By Families of SMA
This new research funding will support a project at Indiana University School of Medicine to better understand the role of SMN protein in motor axons.

By Families of SMA
This new research funding will support a project at the University of Southern California to better understand the role of astrocytes in SMA disease pathology.

By FSMA
This new research funding will support a project at Johns Hopkins University to learn more about motor axon growth in mouse models of SMA.

By Families of SMA
The SMA community now has 3 clinical trials testing new SMA therapies, and an additional 10 programs in earlier stages of the drug development pipeline.

By Families of SMA
Repligen Corporation has initiated a Phase 1b clinical study of RG3039, a novel small molecule drug candidate for the potential treatment of spinal muscular atrophy (SMA).

By Families of SMA
Families of Spinal Muscular Atrophy (FSMA) is dedicated to creating a treatment and cure for Spinal Muscular Atrophy (SMA) by funding and advancing a comprehensive research program.

By Families of SMA
Families of SMA is pleased to announce the award of up to $750,000 for an important new grant to Dr. Brian Kaspar at Nationwide Children’s Hospital.

By Families of SMA
The 12th annual Concert for a Cure event to be held on May 12th, 2012 is aiming to reach the incredible milestone of raising $1,000,000 for Spinal Muscular Atrophy (SMA) Research.

By Families of SMA
Repligen Corporation (NASDAQ:RGEN) today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety profile of RG3039, a novel small molecule drug candidate for the potential treatment of SMA.

By Families of SMA
With the 9th Annual Jacob’s Run, Walk & Roll Event to be held on April 1st, The Jacob Isaac Rappoport Foundation is aiming to reach the milestone of raising $1,000,000 for Spinal Muscular Atrophy (SMA) Research.

By Families of SMA
Developing new therapies to treat and ultimately cure SMA is the driving force behind Families of SMA. To achieve this goal, Families of SMA aggressively invests in drug development research.

By Families of SMA
Nutrition Basics: Fostering Health and Growth for Spinal Muscular Atrophy is Families of SMA’s newest release of the SMA Care Series Booklets, which are provided free of charge to all SMA families, as well as SMA Care Providers worldwide.

By FSMA
Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study of ISIS-SMNRx in patients with spinal muscular atrophy (SMA). Isis is developing ISIS-SMNRx as a potential treatment for all types of SMA.

By Stylish Stagers, Inc.
Dream Room Makeovers, Inc with Stylish Stagers, Inc. to Remodel Union, NJ Home in One Day!

By Families of SMA
Awards to help develop new therapies for SMA. These new awards encompass $745,000 for the basic research portion of the $3 Million in new research funding that FSMA announced earlier this year.

By Mama Bracelets, LLC
Mama Bracelets' owners launch SMA Awareness bracelets in efforts to fund research to cure SMA as their daughter has been recently diagnosed with SMA Type 2.

By FSMA
The new funding awards will be allocated into three distinct research areas: 1)Basic Research to understand the disease, 2)Drug Discovery to develop new SMA therapies, and 3)Clinical Research to provide the means to test new drugs effectively.

By Families of SMA
Boynton Beach residents Shaina and Adi Rappoport have served as the event organizers since 2002 when their son, Jacob, passed way from SMA (Spinal Muscular Atrophy) related complications. Jacob was nine months old.

By Families of SMA
As 2010 comes to a close, we wanted to thank you for your donations and efforts that have supported our research programs and family services.

By Families of SMA
In response to our October Request for Proposals (RFP) for new drug programs to develop therapies for Spinal Muscular Atrophy we received nine Letters of Intent for potential programs.

By Families of SMA
The MDA has committed to invest funds in the FSMA Quinazoline Program at Repligen Corporation to assist in advancing the program to an IND filing with the FDA. FSMA began the Quinazoline, or DcpS inhibitor RG3039, program in 2000.

By Kids Wish Network
A boy suffering from spinal muscular atrophy has his wish to visit the Florida theme parks granted through national children’s charity Kids Wish Network.

By Families of SMA
Families of SMA announces Request for Proposals (RFP) for new drug programs to develop therapies for Spinal Muscular Atrophy. FSMA is aiming to fund two new preclinical drug development programs in 2011, with more to follow.

By Families of Spinal Muscular Atrophy
All across the United States volunteers will come together to raise funds for critical SMA research and patient support programs.

By Fight SMA
Richmond-based FightSMA announced today a new fundraising campaign for spinal muscular atrophy gene therapy, “Realizing the Dream.”

By Fight SMA
A nonprofit dedicated to developing a treatment for the deadly childhood crippler spinal muscular atrophy (SMA), is awarding a $250,000 research grant to Dr. Brian Kaspa of The Ohio State University.

By Fight SMA and the Gwendolyn Strong Foundation
Thousands are using Tweet for a Cure to voice their support for Spinal Muscular Atrophy (SMA) research.

By Fight SMA
Fight SMA Publishes Web Video from 2009 Spinal Muscular Atrophy Conference

By Steve Mullen
Fight SMA is celebrating another successful annual conference.

By EndGame Public Relations, LLC
Fight SMA is providing a free live webcast of two seminars from this year’s Family and Friends Annual Spinal Muscular Atrophy Conference in Washington D.C.

By Steve Mullen / Fight SMA
One of the exciting items in an upcoming charity auction for Fight SMA (http://www.fightsma.org) is an incredibly hard-to-find set of six box seats to the Kentucky Derby. Absentee bidding is available!

By Steve Mullen / Fight SMA
An update of an earlier story about the Fight SMA Spinal Muscular Atrophy National Conference, held April 22-27 in Washington D.C.

By Steve Mullen / EndGame Public Relations, LLC
Families from all over the nation are traveling to the nation’s capital for the the twelfth Fight SMA Annual Conference, with a goal of advancing the fight against the deadly disease spinal muscular atrophy (SMA).

By Steve Mullen / EndGame Public Relations LLC
Fight SMA (http://www.fightsma.org), has launched the first podcast to focus on inspirational stories about people fighting spinal muscular atrophy (SMA), the leading genetic killer of children under two.



Page:
  • 1

Page updated every 10 minutes


  1. SiteMap
  2. Contact PRLog
  3. Privacy Policy
  4. Terms of Service
  5. Copyright Notice
  6. About
  7. Advertise
Like PRLog?
9K2K1K
Click to Share